No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis

被引:0
|
作者
Blok, P
Craanen, ME
Dekker, W
Offerhaus, GJA
Tytgat, GNJ
机构
[1] Westeinde Ziekenhuis, Dept Pathol, NL-2501 CK The Hague, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Gastroenterol, NL-1066 CX Amsterdam, Netherlands
[4] Kennemer Gasthuis, Dept Internal Med, NL-2035 RC Haarlem, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands
来源
JOURNAL OF PATHOLOGY | 1998年 / 186卷 / 01期
关键词
early gastric cancer; p; 53; MDM2; carcinogenesis; immunohistochemistry;
D O I
10.1002/(SICI)1096-9896(199809)186:1<36::AID-PATH150>3.0.CO;2-R
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inactivation of wild-type p53 during gastric carcinogenesis is usually caused by mutations within exons 5-8 of the p53 gene leading to mutated, usually immunohistochemically detectable p53 proteins, However, functional inactivation of wild-type p53, mimicking mutational inactivation, may also result from binding to overexpressed MDM2 protein, While these two mechanisms of p53 inactivation are considered to be mutually exclusive, no data exist as to whether MDM2 overexpression occurs during gastric carcinogenesis. MDM2 protein overexpression was therefore studied in relation to p53 protein accumulation in gastric carcinogenesis. Forty-five paraffin-embedded gastrectomy specimens from early gastric carcinomas were examined for the presence of chronic active gastritis, chronic atrophic gastritis, subtypes of intestinal metaplasia, and dysplasia, The Lauren type was reassessed for all early carcinomas. p53 protein accumulation was examined using the monoclonal antibody DO-7. MDM2 protein overexpression was assessed with the monoclonal antibody SMP-14. Complete absence of nuclear p53 protein accumulation was observed in chronic active gastritis, chronic atrophic gastritis, and intestinal metaplasia, irrespective of the subtype, In gastric dysplasia (one mild, two moderate, one severe), only severe dysplasia was p53-positive, Intestinal-type (n=20) and diffuse-type early gastric carcinoma (n=25) were p53-positive in 70 and 52 per cent of the cases, respectively. MDM2 protein overexpression was not observed during gastric carcinogenesis, either in the p53-positive or in the p53-negative cases, In conclusion, it appears that functional inactivation of wild-type p53 by MDM2 protein overexpression plays no role in (early) gastric carcinogenesis. (C) 1998 John Wiley & Sons, Ltd.
引用
收藏
页码:36 / 40
页数:5
相关论文
共 50 条
  • [21] Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations
    Yu, Qiong
    Li, Yan
    Mu, Kun
    Li, Zhishuang
    Meng, Qingyong
    Wu, Xiaojuan
    Wang, Yan
    Li, Li
    DIAGNOSTIC PATHOLOGY, 2014, 9
  • [22] Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations
    Qiong Yu
    Yan Li
    Kun Mu
    Zhishuang Li
    Qingyong Meng
    Xiaojuan Wu
    Yan Wang
    Li Li
    Diagnostic Pathology, 9
  • [23] Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells
    Kraus, A
    Neff, F
    Behn, M
    Schuermann, M
    Muenkel, K
    Schlegel, J
    INTERNATIONAL JOURNAL OF CANCER, 1999, 80 (06) : 930 - 934
  • [24] Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein
    Landers, JE
    Cassel, SL
    George, DL
    CANCER RESEARCH, 1997, 57 (16) : 3562 - 3568
  • [25] Mdm2 gene amplification in gastric cancer correlation with expression of mdm2 protein and p53 alterations
    Günther, T
    Schneider-Stock, R
    Häckel, C
    Kasper, HU
    Pross, M
    Hackelsberger, A
    Lippert, H
    Roessner, A
    MODERN PATHOLOGY, 2000, 13 (06) : 621 - 626
  • [26] Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
    Walter, Robert F. H.
    Werner, Robert
    Wessolly, Michael
    Mairinger, Elena
    Borchert, Sabrina
    Schmeller, Jan
    Kollmeier, Jens
    Mairinger, Thomas
    Hager, Thomas
    Bankfalvi, Agnes
    Christoph, Daniel C.
    Eberhardt, Wilfried E. E.
    Ploenes, Till
    Aigner, Clemens
    Schmid, Kurt W.
    Wohlschlaeger, Jeremias
    Mairinger, Fabian D.
    JOURNAL OF ONCOLOGY, 2018, 2018
  • [27] OVEREXPRESSION OF P53 AND MDM2 PROTEINS IN CERVICAL NEOPLASIA
    LUKAS, Z
    VOJTESEK, B
    ANTON, M
    PICKSLEY, SM
    KUBALEK, V
    FOLIA BIOLOGICA, 1995, 41 (3-4) : 197 - &
  • [28] Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells
    Geng, Qian-Qian
    Dong, Dan-Feng
    Chen, Nan-Zheng
    Wu, Yin-Ying
    Li, En-Xiao
    Wang, Jie
    Wang, Shao-Meng
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 43 (06) : 1935 - 1942
  • [29] THE EXPRESSION OF THE MDM2 GENE, A P53 BINDING-PROTEIN, IN THYROID CARCINOGENESIS
    ZOU, MJ
    SHI, YF
    ALSEDAIRY, S
    HUSSAIN, SS
    FARID, NR
    CANCER, 1995, 76 (02) : 314 - 318
  • [30] Low SKP2 expression is predictive of sensitivity to an MDM2 antagonist in p53 wild-type AML
    Kucia-Tran, J.
    Bevan, L.
    Chessari, G.
    Fazal, L.
    Ferrari, N.
    Lyons, J.
    Saini, H.
    Wallis, N.
    Ward, G.
    Ahn, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S83 - S84